Literature DB >> 12112408

PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor.

B Bencherif1, C J Endres, J L Musachio, A Villalobos, J Hilton, U Scheffel, R F Dannals, S Williams, J J Frost.   

Abstract

PET and [(11)C]CP-126,998, an N-benzylpiperidinebenzisoxazole, were used to image brain acetylcholinesterase (AChE) distribution in healthy controls before and after administration of 5 mg donepezil p.o., a reversible AChE inhibitor. Logan plots were used to compute distribution volumes (V(T)). The V(T) of [(11)C]CP-126,998 was highest in the basal ganglia and cerebellum and lowest in the cerebral cortex, thalamus, amygdala, and hippocampus. The regional V(T) values correlated well with AChE concentration measured in vitro. Donepezil, given 4 h before PET scanning, induced a substantial inhibition of [(11)C]CP-126,998 binding (43-62%) in all brain regions when compared to the baseline PET study. The results of this study indicate that PET imaging of [(11)C]CP-126,998 may be useful in quantifying the distribution of regional brain AChE. This new PET radiotracer may potentially be employed in the diagnosis and treatment of patients with disorders of cholinergic neurotransmission, such as Alzheimer's disease. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112408     DOI: 10.1002/syn.10072

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  9 in total

1.  An improved radiosynthesis of O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer.

Authors:  Kiel D Neumann; Charles M Thompson; Joseph E Blecha; John M Gerdes; Henry F VanBrocklin
Journal:  J Labelled Comp Radiopharm       Date:  2017-05-15       Impact factor: 1.921

2.  Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; R A Koeppe; C C Meltzer; G Constantine; J G Davis; C A Mathis; S T Dekosky; R Y Moore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

3.  Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.

Authors:  Kathryn A Chung; Brenna M Lobb; John G Nutt; Fay B Horak
Journal:  Neurology       Date:  2010-09-01       Impact factor: 9.910

4.  Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome.

Authors:  Jennifer L Bruno; Sm Hadi Hosseini; Amy A Lightbody; Mai K Manchanda; Allan L Reiss
Journal:  J Psychopharmacol       Date:  2019-07-02       Impact factor: 4.153

5.  In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.

Authors:  Nobuyuki Okamura; Yoshihito Funaki; Manabu Tashiro; Motohisa Kato; Yoichi Ishikawa; Masahiro Maruyama; Hiroyasu Ishikawa; Kenichi Meguro; Ren Iwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

Review 6.  Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease.

Authors:  Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 7.  Brain investigation and brain conceptualization.

Authors:  Alberto Redolfi; Paolo Bosco; David Manset; Giovanni B Frisoni
Journal:  Funct Neurol       Date:  2013 Jul-Sep

Review 8.  PET Radioligands for Imaging of Tau Pathology: Current Status.

Authors:  Yearn Seong Choe; Kyung-Han Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-10-02

9.  Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer.

Authors:  Silvano Gnesin; Joachim Müller; Irene A Burger; Alexander Meisel; Marco Siano; Martin Früh; Matthias Choschzick; Cristina Müller; Roger Schibli; Simon M Ametamey; Philipp A Kaufmann; Valerie Treyer; John O Prior; Niklaus Schaefer
Journal:  EJNMMI Res       Date:  2020-04-08       Impact factor: 3.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.